HC Wainwright Issues Negative Outlook for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Harrow in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.20 per share for the quarter, down from their previous estimate of $0.29. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q4 2026 earnings at $0.40 EPS.

A number of other analysts have also recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday. LADENBURG THALM/SH SH lifted their price target on Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Finally, Cantor Fitzgerald cut their price objective on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $71.14.

Harrow Price Performance

NASDAQ:HROW opened at $39.22 on Thursday. The stock has a market capitalization of $1.46 billion, a PE ratio of -230.69 and a beta of 0.05. Harrow has a 1-year low of $20.85 and a 1-year high of $54.85. The firm has a fifty day simple moving average of $48.19 and a 200 day simple moving average of $43.76. The company has a current ratio of 2.20, a quick ratio of 2.52 and a debt-to-equity ratio of 4.67.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Monday, March 2nd. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.23). Harrow had a positive return on equity of 36.51% and a negative net margin of 1.89%.The company had revenue of $89.09 million for the quarter, compared to analyst estimates of $88.42 million.

Hedge Funds Weigh In On Harrow

A number of large investors have recently made changes to their positions in HROW. Vanguard Group Inc. boosted its stake in Harrow by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock valued at $94,162,000 after purchasing an additional 50,889 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Harrow by 4.7% during the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock worth $24,765,000 after buying an additional 36,724 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Harrow by 31.5% in the second quarter. Marshall Wace LLP now owns 564,876 shares of the company’s stock valued at $17,251,000 after acquiring an additional 135,202 shares during the period. Penn Capital Management Company LLC grew its stake in shares of Harrow by 20.5% in the fourth quarter. Penn Capital Management Company LLC now owns 392,067 shares of the company’s stock valued at $19,257,000 after acquiring an additional 66,589 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Harrow by 32.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 370,548 shares of the company’s stock worth $18,159,000 after acquiring an additional 90,331 shares during the period. Institutional investors own 72.76% of the company’s stock.

Harrow News Roundup

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Company reported record 2025 results with strong revenue and EBITDA growth, supporting the longer‑term story of rising sales across key ophthalmic product lines. Harrow Health Posts Record 2025 Results, Sets 2026 Outlook
• Positive Sentiment: H.C. Wainwright raised its price target to $70 with a “buy” rating, signaling some analysts still see substantial upside. H.C. Wainwright PT Raised to $70
• Positive Sentiment: Management will present at the Leerink Partner’s 2026 Global Healthcare Conference (Mar 10), giving investors fresh management commentary and Q&A access. Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
• Neutral Sentiment: Cantor Fitzgerald trimmed its target slightly (from $94 to $91) but kept an overweight rating — a modest calibration rather than a rejection of the thesis. Cantor Fitzgerald PT Change
• Neutral Sentiment: Earnings call transcripts and analyst notes highlight strong top‑line growth and adjusted EBITDA gains, but also point to mix effects (customer stocking and product transitions) that complicate the forward picture. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Shares initially gapped down after the quarterly earnings release, driven by an EPS miss and investor disappointment despite revenue growth. Harrow Shares Gap Down on Disappointing Earnings
• Negative Sentiment: Harrow’s FY‑2026 revenue guidance of $350M–$365M is materially below consensus (~$394M), a central reason for near‑term negative reaction as investors reassess growth pacing. Guidance and Post‑Earnings Analysis
• Negative Sentiment: At least one independent analyst piece downgraded HROW to “Sell,” citing low margins, high leverage/interest expense and reliance on one‑time stocking to boost results — increased risk to cash flow if growth requires heavier spending. Seeking Alpha Downgrade

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.